ARTICLE
https://doi.org/10.1038/s41467-021-23274-x OPEN
A human antibody selective for transthyretin
amyloid removes cardiac amyloid through
phagocytic immune cells
✉
Aubin Michalon 1 , Andreas Hagenbuch1, Christian Huy1, Evita Varela 1, Benoit Combaluzier1,
Thibaud Damy2, Ole B. Suhr 3, Maria J. Saraiva 4, Christoph Hock1,5, Roger M. Nitsch1,5 & Jan Grimm 1
0():,;
123456789 Transthyretin amyloid (ATTR) cardiomyopathy is a debilitating disease leading to heart
failure and death. It is characterized by the deposition of extracellular ATTR ﬁbrils in the
myocardium. Reducing myocardial ATTR load is a therapeutic goal anticipated to translate
intorestoredcardiacfunctionandimprovedpatientsurvival.Forthispurpose,wedeveloped
theselectiveanti-ATTRantibodyNI301A,arecombinanthumanmonoclonalimmunoglobulin
G1. NI301A was cloned following comprehensive analyses of memory B cell repertoires
derived from healthy elderly subjects. NI301A binds selectively with high afﬁnity to the
disease-associatedATTRaggregatesofeitherwild-typeorvariantATTRrelatedtosporadic
or hereditary disease, respectively. It does not bind physiological transthyretin. NI301A
removes ATTR deposits ex vivo from patient-derived myocardium by macrophages, as well
asinvivofrommicegraftedwithpatient-derivedATTRﬁbrilsinadose-andtime-dependent
fashion. The biological activity of ATTR removal involves antibody-mediated activation of
phagocyticimmunecellsincludingmacrophages.Thesedatasupporttheevaluationofsafety
and tolerability of NI301A in an ongoing phase 1 clinical trial in patients with ATTR
cardiomyopathy.
1Neurimmune,Schlieren,Switzerland.2ReferralCenterforCardiacAmyloidosisandDepartmentofCardiology,HenriMondorUniversityHospital,
Créteil,France.3DepartmentofPublicHealthandClinicalMedicine,UmeaUniversity,Umea,Sweden.4i3S-InstitutodeInvestigaçãoeInovaçãoemSaúde
&IBMC-InstitutodeBiologiaMoleculareCelular,Porto,Portugal.5InstituteforRegenerativeMedicine(IREM),UniversityofZurich,Zurich,Switzerland.
✉
email:aubin.michalon@neurimmune.com
NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications 1

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
T
ransthyretin (TTR) amyloidosis is a systemic disease ELISAformat.Again,NI301AboundwithhighafﬁnitytoATTR
characterized by the accumulation of TTR amyloid oligomerswithEC valuesinthelownanomolarrange(EC for
50 50
(ATTR) in myocardium, peripheral nerves, and various ATTRwt=3.7nM, ATTR-V30M = 12.8 nM and for ATTR-
other tissues, causing congestive heart failure, polyneuropathy, V122I=3.7nM). NI301A did not bind to native TTR tetramers
and death1. Sporadic and hereditary forms of the disease are in their physiological conformation (Fig. 1c).
characterized by the deposition of wild-type TTR (TTRwt) and Surface plasmon resonance (SPR) analyses of binding kinetics
mutated variants of TTR (TTRv), respectively. TTR is a hepatic showed that NI301A bound ATTRwt oligomers in solution with
thyroxine and retinol-transporting protein secreted into the an equilibrium dissociation constant (K ) of 1.2nM, with rapid
D
blood2. It can partially unfold and aggregate into ATTR ﬁbrils; association and slow dissociation (k =2.1×104 M−1s−1, k =
a d
these consists of stable β-pleated sheet structures3. Extracellular 2.6×10−5 s−1; Fig. 1d). Biolayer interferometry (BLI) yielded
myocardial ATTR deposits accumulate in massive amounts similarresultsforATTRv:NI301AboundATTR-V30Moligomers
impacting such mechanical properties of the myocardium as in solution with a K of 2.5nM (k =1.7×104M−1s−1, k =
D a d
diastolic relaxation followed by systolic impairments during 4.3×10−5s−1) and ATTR-V122I oligomers with a K of 3.6nM
D
progression of the disease. In peripheral sensorimotor neurons, (k =2.2×104M−1s−1, k =7.8×10−5s−1; Fig. 1e). Consistent
a d
ATTR deposits are causing polyneuropathy, which are, together with its conformation selectivity indicated by sandwich ELISA,
with cardiomyopathy, the major clinical manifestations of TTR NI301A did not bind physiological native tetramers of either
amyloidosis4. Most sporadic and many genetic amyloidosis are TTRwt or TTRv.
associated with both cardiomyopathy and polyneuropathy. Rare NI301A’s selectivity for ATTR was further conﬁrmed by dot
pure forms of either syndrome include the TTR V122I variant blotanalyses:NI301AboundﬁbrilsofATTRwtandATTR-V20I,
with dominating cardiomyopathy and the TTR-V30M variant V30M, L55P, S77Y, S112I, Y116S, T119M, and V122I immobi-
predominantlyassociatedwithpolyneuropathy5.Epidemiological lized on nitrocellulose membranes, but not the cognate native
studies indicate that TTR amyloidosis with cardiomyopathy TTRtetramers(Fig.1f).Incontrast,anon-selectivecontrolanti-
(ATTR-CM) is likely massively underdiagnosed. Data from Fin- TTR antiserum (Dako A0002) bound both ATTR ﬁbrils and
land, USA, Spain, and France consistently indicate that cardiac native TTR tetramers.
TTRamyloidosiscauses5–13%ofallheartfailureswithpreserved Usingoverlappingpeptidearrays,theNI301A-bindingepitope
ejection fraction or hypertrophic cardiomyopathies6–11. wasdeterminedasthelinearpeptidesequenceWEPFAlocatedin
CurrenttreatmentsofTTRamyloidosisincludestabilizationof position 41–45 of mature TTR protein (Supplementary Fig. 1).
TTRinitsnaturallyfoldedphysiologicalformandgenesilencing, Time-course aggregation studies of in vitro-generated ATTR-
thus preventing unfolding, aggregation, and deposition in target V30M ﬁbrils separated by semi-native polyacrylamide gel
tissues12. To remove pre-existing ATTR from affected tissues in electrophoresis(PAGE)characterizedNI301Abindingtospeciﬁc
patients with TTR amyloidosis, we developed the human oligomeric ATTR species: NI301A bound dimers, trimers,
monoclonal antibody NI301A selectively targeting ATTR aggre- tetramers, as well as higher-order ATTR aggregates (Fig. 1g).
gates. By using high-throughput screening of human memory Asexpected,NI301AdidnotreactwithnativeTTRtetramersbut
B-cell libraries, we generated a collection of ATTR-binding detected misfolded ATTR monomers exposing the NI301A-
antibodies selected for high-afﬁnity binding to ATTR, amyloid- binding epitope that is hidden in the native monomer. In
removal activity, and absent binding to naturally folded, contrast,thenon-selectivecontrolantiserumDakoA0002bound
physiological TTR. This functional selection process led to the both the misfolded monomer and the native tetramer. The
identiﬁcation of NI301A. NI301A binds to the linear epitope antibody 39-44, described as an amyloid-selective TTR
WEPFA hidden in TTR’s naturally folded conformation, but antibody13, robustly bound dimers and small ATTR oligomers
accessible to antibody binding following unfolding and aggrega- but only poorly to larger ATTR oligomers with residual binding
tion.NI301AbindsATTRdepositsincardiactissuesobtainedat to native TTR tetramers.
autopsy from ATTR-CM patients and triggers ATTR removal The absence of binding to physiological TTR tetramers was
from the post-mortem tissues ex vivo via phagocytosis through further investigated in a series of immunoprecipitation experi-
added human macrophages. In wild-type mice grafted with ments. Whereas Dako A0002 immunoprecipitated native TTR
patient-derived ATTR ﬁbrils, systemically administered NI301A fromhumanplasmaevenat1:10,000dilution,NI301Afailedto
accumulates on the grafts and rapidly removes them via Fcγ- immunoprecipitate TTR from the plasma (Fig. 1h and Supple-
mediated phagocytosis. Together, these data support the clinical mentary Fig. 2).
testing of NI301A (NI006) in patients with ATTR-CM in an
ongoing phase 1 clinical trial (NCT04360434).
NI301A binds ATTR deposits on patient tissues. Immunohis-
tochemistry (IHC) showed that NI301A bound with high-
Results selectivity ATTR deposits on a collection of fresh frozen cardiac
NI301A selectively binds human ATTR. NI301A bound with tissues obtained at autopsy from patients with sporadic ATTR-
highafﬁnityandspeciﬁcitybothATTRwtandATTRvaggregates, CM (Fig. 2a). Consistent with its high selectivity for ATTR,
without binding to their native physiological conformation. NI301Afailedtobindtocardiacnon-ATTRdeposits(A+TTR−),
In enzyme-linked immunosorbent assays (ELISAs) against likely representing light-chain amyloid.
humanATTRﬁbrilspreparedinvitro(Fig.1a)andcoatedtoassay IHC staining with NI301A of fresh frozen salivary gland
plates,NI301AboundATTRwt,aswellasATTR-V30MandATTR- biopsiescollected fromATTRT49I,T60A,I68L,S77T,orV122I
V122I, with high afﬁnities as indicated by EC values in the sub- mutation carriers showed a pronounced staining of ATTR
50
nanomolar range (EC for ATTRwt=0.35nM, ATTR-V30M= deposits in all patients analyzed (Fig. 2b). Furthermore, NI301A
50
0.38nM, and ATTR-V122I=0.15nM; Fig. 1b). NI301A bound bound ATTR deposits in skin biopsies and abdominal fat
similarlytoﬁbrilsofATTR-V20I,L55P,S112I,andS116Y(EC for aspirates collected from hereditary cases of ATTR-V30M
50
ATTR-V20I=0.14nM, ATTR-L55P=0.61nM, ATTR-S112I= amyloidosis with polyneuropathy (Fig. 2c, d). In contrast to the
0.20nM,and ATTR-S116Y=0.24nM;Fig.1b). non-selective anti-TTR antiserum Dako A0002, NI301A did not
Toconﬁrmaggregateselectivityindependentlyofhigh-density bind to native TTR expressed in pancreatic α-cells (Fig. 2c),
coating, ﬁbrils were presented in solution by using a sandwich conﬁrming further the amyloid selectivity of NI301A.
2 NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
a  b 
c  d   ATTRwt  tetr.TTRwt 
e 
ATTR-V30M  tetr.TTR-V30M  ATTR-V122I  tetr.TTR-V122I 
f  NI301A  Dako A0002 
WT  V20I  V30M  L55P S77Y S112I Y116S T119M  V122I  WT  V20I  V30M  L55P S77Y S112I Y116S T119M  V122I 
tetr.TTR  tetr.TTR 
ATTR  ATTR 
g  h 
NI301A  39-44  Dako A0002  Human plasma 
IP  tetr. ATTR 1:1  1:100  1:10’000 
kDa  0  4  24  48  72  96 h  kDa  0  4  24  48  72  96 h  kDa 0  4  24  48  72  96 h  antibody kDa TTR  fibr.  1:10  1:1000 
28- 
NI301A 
188  HMW 188  188  14- 
98  98  98 
28- 
62  - 4  62  62 
Dako 
49  - 3  49  49  A0002 14- 
38  - 2  38  38 
28  28  28 
Isotype  14- 
17  - 1  17  17 
14  14  14 
Fig.1NI301Abindstowild-typeandmutantATTRﬁbrilsinvitro,withabsentbindingtonativeTTRtetramers.aCharacterizationofATTRwtﬁbrils
preparedinvitro:ﬁbrilswerevisualizedbyelectronmicroscopyafter72handboundtheamyloidindicatordyethioﬂavinT.bNI301Abindingtocoated
ATTRwtandATTRvﬁbrilsbyELISA(symbols:meanofduplicates,lines:dataﬁtting).cSandwichELISAusingNI301Aforcaptureanddetectiontomeasure
in-solutionbindingtoATTRandTTRtetramers(meanofduplicates).dSPRanalysisofNI301A-bindingkineticstoATTRwtoligomersandnativeTTRwt
tetramersinsolution.eBLIanalysisofNI301A-bindingkineticstoATTR-V30MandATTR-V122Ioligomers,andnativeTTRvtetramersinsolution.Ford
ande,data(graytoblack)wereﬁttedwitha1:1bindingmodel(redlines).fDotblotanalysisofNI301Abindingtonativetetramersoramyloidaggregates
ofTTRwtandTTRvproteins.Apolyclonal,pan-TTRantibody(DakoA0002)wasusedforcomparison.gAnalysisofTTR-V30Maggregationtimecourse
bysemi-nativeSDS-PAGEfollowedbywesternblottingwithantibodiesNI301A,39-44,andDakoA0002.PositionsofATTRmonomers(1),dimers(2),
trimers(3),tetramers(4),andaggregatesofhighmolecularweight(HMW)aremarked.hImmunoprecipitationwithantibodiesNI301A,DakoA0002,and
humanIgG1isotypecontrolofnativeTTRtetramers(tetr.TTR)orpatient-derivedATTRﬁbrils(ATTRﬁbr.),andserialdilutionsofhumanplasmafrom
healthydonors.
Onpatientmyocardiumamyloidextracts,NI301Areactedwith without amyloid deposits (A−) or amyloid deposits unrelated to
high sensitivity to small, medium, and large ATTR aggregates, TTR (A+TTR−) (Fig. 3). Selective binding to ATTR aggregates
consistent with our results with ATTR-V30M aggregates togetherwithabsentbindingtounrelatedproteinswassustained
prepared in vitro. Consistent with its ATTR selectivity, NI301A following long exposure, further underscoring NI301A’s high
did not bind corresponding preparations from cardiac tissues degree of selectivity (Supplementary Fig. 3).
NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications 3

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
a  NI301A  Dako A0002  Congo red  CR polarization 
ATTRwt 
Case 1 
ATTRwt 
Case 2 
ATTRwt 
Case 3 
A- 
Control 
A+TTR- 
Control 
200 µm 
b  ATTR-T49I  ATTR-T60A  ATTR-I68L  ATTR-S77T  ATTR-V122I 
NI301A 
Congo red 
100 µm 
c  ATTR-V30M  Heathly donor  d  ATTR-V30M #1  ATTR-V30M #2 
Skin  Pancreas  Fat biopsy  Fat biopsy 
NI301A 
Dako 
A0002 
60 µm  100 µm 
Fig.2NI301AbindsTTRamyloidpresentinsporadicandhereditarycasesofATTRamyloidosiswithcardiomyopathyandpolyneuropathy.aIHC
usingNI301Aonfrozenpost-mortemhearttissuescollectedfromthreesporadiccaseswithATTRwtcardiomyopathy,acasewithoutamyloid(A−),and
onewithnon-TTRamyloiddeposits(A+TTR−).ATTRdepositswereidentiﬁedbyCongoredstainingwithbirefringenceandimmunostainingwiththepan-
TTRantibodyDakoA0002.bIHCusingNI301AandCongoredstainingonfrozensalivaryglandbiopsiescollectedfromATTRvcardiomyopathypatients
carryingthevariantsTTR-T49I,T60A,I68L,S77T,andV122I.cIHCusingNI301AandDakoA0002onskinbiopsyfromapatientwithATTR-V30M
polyneuropathyandonhumanpancreastissue.dIHCusingNI301AandDakoA0002onabdominalfataspiratesfromtwopatientswithATTR-V30M
polyneuropathy.
4 NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
NI301A  39-44  Dako A0002  Silver stain 
mis  ATTR+  A-  mis  ATTR+  A-  mis  ATTR+  A-  mis  ATTR+  A- 
TTR  1  2  3  4  5  6  7  8  9  TTR  1  2  3  4  5  6  7  8  9  TTR  1  2  3  4  5  6  7  8  9  TTR  1  2  3  4  5  6  7  8  9 
kDa 
188 
98 
62 
49 
38 
28 
17 
14 
Fig.3NI301AbindssmallandlargeATTRwtaggregatesextractedfrompatienttissues.Semi-nativeSDS-PAGEanalysisoftheamyloidﬁbrilextracts
preparedfromfrozenpost-mortemcardiactissuespresentingTTRamyloid(ATTR+samples,#1–4),noamyloid(A−samples,#5–8),ornon-TTRamyloid
(A+TTR−sample,#9).IdenticalSDS-PAGEgelswereprocessedforwesternblotanalysiswiththeantibodiesNI301A,39-44,andDakoA0002,orstained
withthesilvermethod.ThelowATTRstainingintensityofsample4isconsistentwiththelowamountofTTRamyloidobservedbyIHCinthissample.
The selectivity of NI301A was further conﬁrmed in a human activity, we evaluated the impact of complement activation on
tissue cross-reactivity study using fresh frozen human tissue amyloidclearance.Phagocytosisassaysweredoneinthepresence
arrays. This study did not identify any off-target binding for ortheabsenceofdifferentconcentrationsofeitherfreshorheat-
NI301A at 30µg/mL, the highest concentration tested. No inactivated human plasma. Human plasma triggered a
staining was observed on liver tissue sections, the main organ concentration-dependent increase in ATTR-L55P phagocytosis
producing TTR, further conﬁrming NI301A absent binding to in vitro; heat inactivation of plasma abolished this activity
physiological TTR protein (Supplementary Fig. 4). (Fig.5a).TheaccelerationbyfreshplasmaofATTRphagocytosis
wasconﬁrmedinexvivoassays,resultinginanalmostcomplete
NI301A removes ATTR ﬁbrils by macrophage-mediated pha- removalofcardiacamyloiddepositsbymacrophages(Fig.5b).In
vitro experiments further conﬁrmed complement activation:
gocytosis. By using human macrophages freshly prepared from
peripheral blood mononuclear cells, we established NI301A’s NI301AbindingtocoatedATTRwtﬁbrilsinthepresenceoffresh
biological activity to trigger phagocytosis of ﬂuorescent TTR- human plasma triggered formation of the insoluble complement
factor C5b9, indicating that the complement cascade had been
L55P aggregates. We used TTR-L55P because of its ability to
activated to completion (Fig. 5c). No complement activation
oligomerize under physiological conditions. NI301A triggered
occurred when NI301A was incubated with BSA and plasma,
ATTR-L55Pphagocytosisinaconcentration-dependentmanner,
consistent with a speciﬁc effect of NI301A decorating ATTR
with activity starting at low nanomolar antibody concentrations.
ﬁbrils.
Antibody-mediated phagocytosis of ATTR-L55P oligomers was
impeded by blocking Fc receptors consistent with Fc-mediated
phagocytosis. An isotype control antibody failed to trigger pha- NI301A binds ATTR ﬁbrils in vivo and activates amyloid
gocytosis of ATTR-L55P (Fig. 4a). Flow cytometry experiments
clearance in mice. To characterize the biological activity of
with ATTR-L55P and antibodies labeled with different ﬂuor-
NI301Ainvivo,wedevelopedapatient-derivedamyloidxenograft
escent dyes showed that NI301A, but not the isotype control (PDAX) mouse model. In PDAX mice, ATTR ﬁbrils extracted
antibody,dose-dependentlytriggeredthephagocytosisofATTR-
frompatientmyocardiumtissuesweresubcutaneouslygraftedand
L55P oligomers by macrophages (Fig. 4b and Supplementary ﬂuorescentNI301A-VT680conjugateswereinjectedintravenously
Fig. 5). Confocal microscopy of human macrophages during
(i.v.), to determine the target engagement of human amyloid in
phagocytosis revealed intracellular vesicular localizations of livingmice(Fig.6a).HumanATTRﬁbrilgraftswerethioﬂavinS-
ATTR-L55P and NI301A, suggesting co-localization of ATTR- positive, indicating preserved β-sheet conformation of the ATTR
L55P and NI301A within vesicles (Fig. 4b ).
3 amyloiddeposits.Forty-eighthoursaftergraftingandi.v.antibody
Amyloid deposits in patients consist of multiple proteins, administration, ﬂuorescent NI301A-VT680 dose-dependently
proteoglycans, and the plasma protein Serum Amyloid P (SAP), accumulated on human ATTR ﬁbril grafts and colocalized with
potentially masking ATTR epitopes. To verify that NI301A thioﬂavin S, indicating that it bound to human amyloid in vivo
triggers phagocytosis of patient amyloid deposits, we developed (Fig. 6b). The NI301A-VT680 ﬂuorescence intensity increased
an ex vivo functional assay with fresh frozen myocardium linearlywithdoseovertherangeof0.05–15mg/kg,indicatingthat
sections containing ATTR and incubated them with human
epitopesforantibodybindingwerenotsaturatedwithdosesupto
macrophages in the presence of antibodies. During 14 days of
15mg/kg body weight (Fig. 6c).
incubation,NI301AremovedATTRfromhumanmyocardiumin Forinvivoefﬁcacyexperiments,weproducedthemonoclonal
a concentration-dependent manner. NI301A reduced both the
mouse chimeric antibody ch.NI301A by fusing the human
total number of ATTR deposits and the total area covered by
NI301A variable domains with murine IgG2a constant domain
ATTR deposits by up to 50% (Fig. 4c, d). ATTR removal from sequences. Six hours and 96h following ﬁbril grafting and
patient myocardium tissue sections was speciﬁc for NI301A; the
injectionofch.NI301A,wemeasuredATTRbyIHC.After6hof
isotype control antibody failed to remove ATTR.
antibodytreatment,micepresentedsimilaramountsofATTRper
graft, corresponding to an average 86% of the graft area (range
NI301A-mediated complement activation accelerates amyloid 83.2–89.7%). At this early time point, the ﬁbril grafts were
clearance. To further characterize NI301A’s amyloid-removal inﬁltrated by neutrophils (CD11B+, LY6G+, IBA1−), an
NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications 5

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
a  b b b
1  2  3 
0 nM  10 nM 
0 
5
5
A-
1
30 80 nM  80 nM / no TTR 
NI
nM  200 µm 
ATTR-L55P-488  NI301A 
c  d 
Vehicle  NI301A 10 nM 
500 µm 
Fig.4NI301AactivatesATTRphagocytosisbyhumanmacrophagesonhumanhearttissue.aInvitroATTRphagocytosisassayperformedwithhuman-
derivedmacrophages,ﬂuorescentlylabeledTTR-L55Pprotein,anddifferentconcentrationsofNI301Aorisotypecontrolantibodies,withorwithoutFc-
receptorblockingreagent(FcRblock)(mean±SDoftriplicates).bInvitroATTRphagocytosiswithbothTTR-L55PandNI301Aﬂuorescentconjugates,and
quantiﬁcationofdouble-positivemacrophagesbyFACS.b Dotplots;b quantiﬁcationofdouble-positivecells;b representativedouble-positive
1 2 3
macrophageimagedbyconfocalmicroscopy:blue:Dapi,green:TTR-L55P-atto488,red:NI301A-atto550.cExvivotissueamyloid-removalassay
performedwithhuman-derivedmacrophagesandNI301Aonpatientmyocardiumsections.Representativepairofadjacenttissuesectionstreatedwith
NI301AorvehiclecontainingthioﬂavinS-positiveamyloiddeposits(quantiﬁeddepositsingreen).Whitearrowspointtoamyloiddepositsremovedby
macrophagesinthepresenceofNI301A.dQuantiﬁcationofthioﬂavinS-positiveamyloiddepositnumberandtotalareapertissuesectionfollowing
treatmentwithincreasingconcentrationsofNI301Aorcontrol.Vehiclen=24sections,NI301An=6sectionsperconcentration(mean±SD).One-way
ANOVAandDunnett’smultiplecomparisonstest(meandifferenceand95%CI).Numberofdeposits:F(4,43)=4.73,P=0.003;1.0nMvs.Vehicle:
−85.08(−164.4to−5.8),*P=0.031;10nMvs.Vehicle:−117.4(−196.7to−38.1),**P=0.0017.Totaldepositarea:F(4,43)=1.91,P=0.13;10nMvs.
Vehicle:−278,662(−560,983to3660),°P=0.054.
immediate response characteristic of wound-healing process 1mg/kgintraperitoneally(i.p.).ch.NI301Aﬁbrilremovalactivity
(Supplementary Fig. 6). After 96h, the isotype-treated control wasmaintainedinthepresenceoftafamidis;tafamidisalonehad
groupshowedamoderate,butstatisticallysigniﬁcant,decreasein no effect on ATTR ﬁbril removal (Fig. 6f).
graft ATTR area, reﬂecting a spontaneous reaction against the
human ATTR ﬁbril grafts. All three doses (0.5, 5, and 50mg/kg
Frequency of cardiac ATTR in autopsy samples from patients
body weight) of ch.NI301A further reduced ATTR in a dose-
with heart failure. To investigate the frequency of ATTR cardi-
dependent manner. Both the 5 and 50mg/kg doses removed the
amyloid ﬁbrils almost completely, down to background levels of omyopathyandfurthertestthecapacityofNI301AtobindATTR
in patients, we analyzed 80 autopsy heart tissue samples from
about 7% of the graft area. Even the low dose of 0.05mg/kg ch.
patients who died of heart failure at ages ≥80 years. Varying
NI301A trended to remove amyloid, but its effect was not
statistically signiﬁcant (Fig. 6d). At this late time point (96h), amounts of Congo red and TTR antibody 39-44 IHC-positive
ATTR ﬁbril grafts were entirely inﬁltrated by phagocytic ATTRdepositswerepresentin24(30%)cases.Theabundanceof
monocytes (CD11B+, LY6G−, IBA1−) (Supplementary Fig. 6). ATTR deposits was low in 11 samples (14%), moderate in
4 samples (5%), and high in 9 samples (11%) (Supplementary
Mice did not exhibit any sign of overt toxicity.
Table 1 and Supplementary Fig. 7). NI301A detected ATTR
Collectively,thelinearincreaseintargetbindingovertherange
of 0.05–15mg/kg and the strong biological activity starting at deposits by IHC in all 24 ATTR-positive samples.
dosesof5mg/kgbodyweightsuggestedthattargetsaturationwas
not required for the maximum activation of ﬁbril removal by Discussion
phagocytic immune cells in PDAX mice. The results of this study show that NI301A, a human-derived
A similar in vivo experiment was performed using the Fc- amyloid-selective antibody targeting both ATTRwt and ATTRv,
inactive variantch.NI301A-LALAPGat10mg/kg i.v.In contrast removed pathological ATTR deposits from patient myocardium
to treatment with ch.NI301A, which triggered ATTR ﬁbril tissues ex vivo, as well as patient-derived ATTR ﬁbril grafts in
removal, treatment with ch.NI301A-LALAPG had no effect on mice in vivo. Characterization of the binding properties of
ﬁbril removal in vivo, indicating that effector functions are NI301A demonstrated (1) that NI301A bound ATTR oligomers
required for antibody-mediated amyloid clearance (Fig. 6e). andﬁbrilswithsub-nanomolarEC ,(2)thatNI301Awashighly
50
Theeffect of ch.NI301A was also evaluated at 10mg/kg i.v. in selective for the amyloid conformation of TTR, and (3) that
thepresenceoftheTTRstabilizertafamidis,administereddailyat NI301A similarly bound both wild-type and variant ATTR
6 NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
Plasma concentration
a b
1 0.8% 2.4% 7.2%
e
cl
hi
e
V
M
n
0 
1
A 
1
0
3
NI
b 5 mm c
2
Fig.5Antibody-mediatedcomplementactivationincreasesATTRphagocytosisandtissueamyloidclearance.aInvitroATTRphagocytosisassay
performedwithhuman-derivedmacrophages,TTR-L55P-atto488,andNI301Ainthepresenceoffreshorheat-inactivatedhumanplasmaatdifferent
concentrations(mean±SDofquadruplicates).bExvivotissueamyloid-removalassayperformedwiththreeconcentrationsoffreshhumanplasma.
b RepresentativepairsofadjacenttissuesectionstreatedwithNI301Aorvehicle.b Quantiﬁcationofnumberandareaofamyloiddepositspertissue
1 2
section.n=5–6sectionspercondition(mean±SD).Two-wayANOVAformainfactorsPlasmaconcentrationandAntibody,andBonferroni’smultiple
comparisonstestofNI301Atovehicleconditions(meandifferenceand95%CI).ForthenumberofATTRdeposits:Plasmaconcentration:F(2,26)=16.04,
P<0.0001;Antibody:F(1,26)=84.53,P<0.0001;NI301Avs.Vehicleusing0.8%plasma:−309.4(−461.5to−157.3),***P<0.0001;NI301Avs.Vehicle
using2.4%plasma:−302.6(−454.7to−150.5),***P<0.0001;NI301Avs.Vehicleusing7.2%plasma:−308(−446.9to−169.1),***P<0.0001;NI301A
vs.Isotypeusing7.2%plasma:−238.3(−367.7to−109.0),***P=0.0007.Fortotaldepositarea:plasmaconcentration:F(2,26)=6.85,P=0.0041;
Antibody:F(1,26)=26.56,P<0.0001;NI301Avs.Vehicleusing2.4%plasma:−522,593(−899,939to−145,246),**P=0.0046;NI301Avs.Vehicle
using7.2%plasma:−497,895(−842,364to−153,427),**P=0.0031;NI301Avs.Isotypeusing7.2%plasma:−398,001(−734,405to−61,596),*P=
0.02.cInvitrocomplementactivationassayofNI301AinfreshhumanplasmausingcoatedATTRwtﬁbrilsorbovineserumalbumine(BSA)astarget,
followedbyimmunodetectionofthecomplementactivationproductC5b9(meanofduplicates).
(Fig. 1). The latter was conﬁrmed by IHC using tissues collected generatedusingasimilarapproach16.Fromaclinicalperspective,
frompatientswithsporadicorhereditaryATTRamyloidosiswith theabsentbindingtophysiologicalTTRtetramersandmonomers
cardiomyopathy or polyneuropathy (Fig. 2). may be a key requirement for therapeutic efﬁcacy of NI301A, as
Selectivebindingtowild-typeandvariantATTRoligomersand off-targetbindingtonativeTTRpresentathighconcentrationin
ﬁbrilsisconsistentwithresultsofstructuralstudiesshowingthat plasma could lead to impaired pharmacokinetics and reduced
pathogenicmutationsintheTTRpolypeptidesequencecanaffect target engagement with tissue ATTR.
thestabilityofnativetetramers,thuspromotingtheirdissociation In human cardiomyopathy patients, large amounts of ATTR
into monomers. These mutations, however, do not modify the deposits accumulate in the myocardium. By using in vitro and
propensity of TTR to misfold, oligomerize, and aggregate into ex vivo systems, we established that NI301A induces ATTR
amyloid-forming ﬁbrils14, suggesting that the pathogenic phagocytosis in an antibody concentration-dependent manner
mechanisms of accelerated amyloid formation in the genetic that is mediated by engagement of Fcγ receptors on human
formsofthedisease isrelatedto decreased stability ofthenative macrophages (Fig. 4). On heart tissue sections from human car-
TTR tetramer. diomyopathy patients, NI301Adose-dependently removed tissue
We conﬁrmed the conformation selectivity of NI301A with amyloid by triggering phagocytosis by human macrophages,
independentassaysincludingsandwichELISA,BLIandSPR,dot attainingmorethan50%amyloidremovalwithina2-weektime.
blot, semi-native PAGE and western blottings, IHC, and immu- This effect size is substantial, considering the absence of replen-
noprecipitation from human plasma (Figs. 1 and 2). This strin- ishmentofmacrophagesinourexvivoexperiments(Fig.4).Low
gent selectivity for pathological TTR conformations results from concentrations of fresh human plasma further increased
NI301A binding a hidden linear epitope, which is not accessible antibody-mediated amyloid removal from patient tissues, sug-
on the native TTR conformation but becomes accessible upon gesting synergistic effects throughcomplementfactorsin plasma
misfolding of β-pleated sheets into a loop protruding from the (Fig. 5).Thecomplement systemcancontribute to theclearance
amyloid core3,15. Conformation selectivity can be further of amyloid in vivo by a combination of direct protease activity
enhanced by high avidity binding to repetitive epitopes that are and trans signaling, triggering the formation of macrophage-
displayed in oligomers and amyloid ﬁbrils as was described for derivedmultinucleatedgiantcellswiththecapacitytoengulfvery
the β-amyloid-selective antibody aducanumab, which was large particles17. Consistent with intact complement activity,
NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications 7

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
NI301A-VT680  Isotype-VT680 
a  b 
0.05 mg/kg  0.5 mg/kg  5 mg/kg  15 mg/kg  15 mg/kg 
Patient’s 
ATTR fibrils  PI 
A
D
S 
Treatment  o-
c  hi
T
0 
8
6
T
V
y 
a
erl
v
O
500 µm 
ch.NI301A 96 hours 
d  6 hours 
All treatment groups  0.05 mg/kg   0.5 mg/kg  
#31-50  #57-40  #52-50 
Isotype 96 hours 
50 mg/kg   5.0 mg/kg   50 mg/kg  
#34-39  #46-30  #38-50 
300 µm 
e  f 
Isotype  ch.NI301A-LALAPG  ch.NI301A 
50 µm 
fresh, but not heat-inactivated, plasma increased NI301A- ATTR cardiomyopathy is characterized by large accumulation
mediated phagocytosis of ATTR by macrophages (Fig. 5). of extracellular ATTR ﬁbrils in the myocardium, which can lead
Finally, NI301A was active in vivo. It accumulated dose- toadoublingofextracellularvolumesinpatientsascomparedto
dependently on human ATTR ﬁbrils grafted into mice. A mur- healthy subjects18,19, an increase of the left ventricle wall thick-
inized chimeric variant of NI301A substantially accelerated the ness from <12mm in healthy subjects to >20mm in advanced
removal of ATTR by phagocytic cells and did not exhibit any patients20,21, and ATTR deposition occupying 30–40% of the
signsofoverttoxicityinthismodel.Ingoodagreementwiththe total myocardiumtissue area22.Mechanically, amyloidﬁbrilsare
in vitro phagocytosis data, antibody-mediated ﬁbril removal remarkably rigid and their resistance to rupture has been com-
in vivo was dose-dependent and required an active Fc domain paredtothatofsteel23.Asaresult,theaccumulationofATTRin
(Fig. 6). Furthermore, the antibody-mediated ﬁbril removal the myocardium causes progressive tissue rigidiﬁcation together
activitywasmaintainedinthepresenceoftafamidis,currentlythe with loss of muscle elasticity. Functionally, this loss in elasticity
only approved therapy for ATTR-CM. can cause diastolic dysfunction during initial disease stages
8 NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
Fig.6Dose-dependentbindingofNI301AonTTRamyloidinvivoandactivationofimmuneclearanceinmice.aSchematicofthepatient-derived
amyloidxenograftmousemodel:ATTRﬁbrilgraftwasplacedsubcutaneouslyonthethighandtreatmentsadministeredi.v.bInvivobindingof
ﬂuorescentlylabeledNI301A-VT680topatient-derivedATTRﬁbrilgrafts48hafteramyloidgraftingandantibodyadministration.cQuantiﬁcationof
NI301A-VT680ﬂuorescenceintensityonATTRgrafts(mean±SDof5miceperdoselevelusing3sectionspermouse).dch.NI301A-mediatedclearance
ofATTRgraftsinvivo.ATTRremainingafter6and96hoftreatmentwasdetectedbyIHCstainingandquantiﬁed(mean±SDofn=4–5micepergroup
using3–6sectionspermouse).One-wayANOVA(F(4,19)=13.6,P<0.001)andDunnett’smultiplecomparisonstest(meandifferenceand95%CI).Ch.
NI301A0.5vs.Isotype:−34.3(−55.0to−13.6),**P=0.001;ch.NI301A5vs.Isotype:−50.9(−72.8to−28.9),***P<0.001;ch.NI301A50vs.Isotype:
−43.4(−64.1to−22.6),***P<0.001.eEvaluationofFc-silentch.NI301A-LALAPGantibodyonATTRgraftremovalinvivo(mean±SDofn=8miceper
groupusing3–4sectionspermouse,allantibodiesat10mg/kgi.v.).One-wayANOVA(F(2,21)=14.2,P=0.0001)andDunnett’smultiplecomparisons
test.Ch.NI301Avs.isotype:−22.4(−34.0to−10.7),***P=0.0003.fEvaluationofch.NI301A+tafamidiscombinationonATTRremovalinvivo(mean±
SDofn=6–8micepergroup,3–4sectionspermouse;antibodiesonceat10mg/kgi.v.andtafamidisdailyat1mg/kgi.p.).Two-wayANOVAformain
factorsAntibodiesandStabilizer,andDunnett’smultiplecomparisonstesttotheisotype+vehiclegroup.Antibody:F(1,25)=52.3,P<0.0001;Stabilizer:
F(1,25)=0.52,P=0.48.Ch.NI301A+vehiclevs.isotype+vehicle:−23.9(−38.2to−9.5),***P=0.001;ch.NI301A+tafamidisvs.isotype+vehicle:
−31.8(−46.1to−17.4),***P<0.0001.
followedbyreductionsinejectionfractionandheartfailure.Both Similartoaducanumab,cinpanemab,andAP101,NI301Aisan
the reduction in left ventricle ejection fraction and the loss of aggregate-selectiveantibodythatwasidentiﬁedbasedonimmune
contractility are strongly correlated with disease severity and repertoire analyses of memory B-cell complements from healthy
reducedsurvivaltime20,24.Severaltherapeuticapproachesforthe elderly subjects. Such antibodies targeting pathogenic conforma-
treatment of ATTR amyloidosis are focused on a slowing or the tions of self-proteins may be generated in response to the age-
prevention of amyloid formation. The TTR stabilizers tafamidis associated accumulation of pathological protein aggregates
and the repurposed anti-inﬂammatory drug diﬂunisal, as well as includingvariousformofamyloid,generatingthepossibilityofa
TTR gene silencers patisiran and inotersen, have achieved sub- physiological mechanism, for elimination of misfolded proteins
stantial reductions or even a complete halt in disease byengagingimmunebiologyotherwisetargetingnon-self,foreign
progression25–28. NI301A has a different mode-of-action that is proteins. As a corollary, antibody-mediated removal of ATTR
targeting the active removal of pre-existing amyloid and may amyloid from heart tissues may well represent an additional
therefore have a potential beyond disease stabilization for func- approach for the treatment of patients with cardiomyopathy
tional improvements by decreasing cardiac muscle stiffness and caused by ATTR amyloidosis. To test this possibility, NI301A
improving heart contractility and elasticity. (NI006)iscurrentlyevaluatedinaphase1clinicaltrialinATTR-
We evaluated the frequency of ATTR cardiomyopathy in CM patients.
elderly male Caucasian patients who died of heart failure with
preserved ejection fraction and found pathologic amounts of Methods
ATTR in 16% of the samples. This high frequency is consistent Antibodyidentiﬁcation,cloning,andrecombinantexpression.cDNAsequences
with published data, indicating that ATTR cardiomyopathy is a encodinghumanATTR-bindingantibodieswerederivedfromade-identiﬁed
massively underdiagnosed condition6–11. NI301A bound ATTR bloodlymphocytelibrarycollectedfromhealthyelderlysubjects.MemoryBcells
deposits in all positive tissues, suggesting a broad applicability wereisolatedandcultivatedasdescribedinSevignyatal.29.HumanmemoryBcells
wereCD22+,CD27+andIgD−,IgM−,CD3−,CD56−,andCD8a−.Theywere
across patients.
screenedbyELISAfortheexpressionofantibodiesbindingtowild-typeand
Antibody-mediated amyloid removal is a novel treatment variantATTR.Positivehitswerecounter-screenedtoexcludeclonescross-reacting
modality. It is currently tested in advanced stages of clinical withunrelatedamyloid-formingproteins.SelectedATTR-reactiveB-cellclones
development with proof-of-mechanism obtained in patients. In weresubjectedtocDNAcloningofIgGheavyandlight-chainvariableregion
Alzheimer’sdisease,theAβ-targetingantibodiesaducanumaband sequences,andsub-clonedintoexpressionvectorsencodinghumanIgG1constant
domainsequences.ExpressionconstructsencodingIgG1heavyandlightchains
gantenerumabachievedsubstantialreductionsinAβplaqueload weretransientlyexpressedinCHO-ScelllineandpuriﬁedbyproteinAafﬁnity
inpatients29,30.Amyloidremovalincreasedwithdoseandtime.It chromatography.
was associated with amyloid-related imaging abnormalities, Humanbloodsamplesfromhealthyelderlysubjectswerecollectedunder
writteninformedconsentandstudyapprovalbytheEthicsCommitteeofthe
potentially a correlate of the biological mechanism of antibody-
CantonofZurich.ThestudywascompliantwiththeHelsinkiDeclaration.
mediated amyloid removal31. Various other antibodies targeting
amyloid or pathological protein aggregates are under clinical
investigation. These include the α-synuclein aggregate-selective PreparationofhumanATTR.HumanTTRwtwasobtainedbypuriﬁcationfrom
humanbloodplasma(Bio-Rad).ThepathogenicTTRproteinvariantsV20I,
antibodies cinpanemab and PRX002/RG7935 for the potential V30M,L55P,S77Y,S112I,Y116S,T119M,andV122Iwereexpressedrecombi-
treatment of Parkinson’s disease32, the anti-τ antibody BIIB076 nantlyinEscherichiacoli(AlexotechandWako);purepreparationsofnon-amy-
for the potential treatment of Alzheimer’s disease33, and the loid,nativeTTRwt,andTTRvtetramerswereobtainedbysize-exclusion
chromatographyonSuperdex75columns,toremovepre-existingmisfoldedpro-
misfolded SOD1-selective antibody AP101 for the potential
teins.ATTRﬁbrilswerepreparedbyaggregatingTTRat200µg/mLin50mM
treatment of amyotrophic lateral sclerosis34. Dezamizumab is a acetate-HCl,100mMKCl,1mMEDTApH3.0for5daysat65°Cundershaking
humanized monoclonal IgG1 antibody binding to native SAP conditionsat1000r.p.m.15.ThisproceduregeneratedthioﬂavinS-positiveﬁbrils
component, a plasma protein identiﬁed in all types of amyloid readilydetectablebyelectronmicroscopy(Fig.1a).Water-solubleATTRoligomers
deposits. In a phase 1 clinical trial conducted in patients with werepreparedwiththeaboveprotocolandbylimitingtheaggregationtimeofTTR
to4hat37°C.
systemic amyloidosis, dezamizumab treatment was associated
with signs of organ response such as decreases in liver stiffness,
which were highly consistent with the macrophage‐dependent Enzyme-linkedimmunosorbentassay.ELISAassaysweredonein96-well
microplates(Corning)coatedwithATTRﬁbrilsandwereblockedwith2%BSA,
phagocytic clearance of amyloid demonstrated in animal
0.1%Tween-20inphosphate-bufferedsaline(PBS)beforeaddingprimaryanti-
models17,38,39. A phase II trial in patients with cardiac amyloi- bodiesinduplicatesforovernightincubationat4°C.Afterwashing,boundanti-
dosis was initiated but terminated prematurely due to an bodiesweredetectedwithhorseradishperoxidase(HRP)-conjugatedanti-human
apparent change in the risk-beneﬁt proﬁle, which might have IgGantibodies(JacksonImmunoresearch)andDAB(3,3'Diaminobenzidine)
substrate.Theabsorbancewasmeasuredusingamultifunctionplatereader
beenrelatedtodezamizumabbindingphysiologicalSAPprotein.
(ThermoFisherVarioskanLuxandSkanIt6.02software).Datawereexportedto
NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications 9

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
Excel(Microsoft)fordatamanagementandwereﬁttedwithalogarithmic Invitroandexvivophagocytosisassays.Macrophagesweredifferentiatedfrom
dose–responsefunctionwithvariableslope(fourparameterlogisticregression, freshhumanmonocytesbyculturingthesefor10–15daysinmacrophageserum-
4PL)usingtheleast-squareregressioninPrism7.03(GraphPad). freemedium(M-SFM,LifeTechnologies)supplementedwithmacrophagecolony-
stimulatingfactor(100ng/mLM-CSF,Miltenyi),orgranulocyteM-CSF(50ng/mL
GM-CSF,Sigma).
CaptureELISA.Streptavidin-coatedplates(Greiner)wereloadedwithbiotinylated Invitrophagocytosiswasdonefor2hat37°Cinthepresenceoffucoidanat0.5
NI301AandblockedbeforetheadditionofATTRorTTRsamplesinduplicatesfor mg/mL,ATTR-L55PlabeledwithAtto488(Sigma)at7µg/mL,NI301A,andisotype
2hincubationatroomtemperature.Afterwashing,boundATTRwasdetected controlatconcentrationsfrom0to80nM.AnFc-receptorinhibitor(Miltenyi)was
withanHRP-conjugatedNI301Aantibodyincombinationwithluminescent usedfornegativecontrolat1:100dilution.Afterwashes,thelevelsofATTR-L55P-
substrate(Biotinylationkit,HRP-labelingkit,andHRPsubstratefromThermo- atto488internalizationweremeasuredwithaﬂuorescenceplatereader(Varioskan
Fisher).Datawereﬁttedusing4PLwith1/y2weighting. Lux,ThermoFischer).AntibodieslabeledwithAtto550(Sigma)werealsousedin
combinationwithﬂuorescence-activatedcellsortingtoquantifydouble-positive
macrophagesonly.Allexperimentswereperformedintriplicates.Forconfocal
Bindingkineticsassays.BindingtosolubleATTRwtoligomerswasdetermined microscopyimaging,experimentsweredonewithmacrophagescoatedoncoverslips.
bySPRonaProteOnXPR36machine(Bio-Rad)at25°CinHBS-Tbuffer,usingan Exvivophagocytosiswasdonewithhumanmacrophageson15µm-thickpost-
anti-humanIgG,Fcγ-speciﬁcantibody(JacksonImmunoresearch)covalently mortemmyocardialsectionsobtainedfromATTR-CMpatients.Tissuesections
coupledtoaGLMsensorchip,tocaptureNI301Aonthesensor.Datawere weremountedonglasscoverslips,usingpairsofadjacentsectionsforantibodyor
analyzedinProteOnManagerv.2.0anddouble-referencedusinginterspotsand vehiclecontrolconditions.TheM-SFM/GM-CSFmediumwassupplementedwith
thebuffer-onlychannel,andﬁttedbyusinga1:1kineticmodel(Langmuirﬁt). interferon-γ(100ng/ml)andlipopolysaccharide(20ng/ml)tostimulate
BindingtosolubleATTRvoligomerswasdeterminedbyBLIonanOctet macrophagephagocyticactivity.Tissuesections(6replicatespercondition)were
RED96machine(PallForteBio).Asthistechnologycircumventstheneedfor incubatedfor14daysat37°C(95%CO,5%O)with50%replacementofthecell
microﬂuidics,itiswellsuitedformeasuringbindingtoproteinaggregates.The culturemediumevery3–4days;theywer2ethend2irectlyﬁxedwith4%PFA,washed,
experimentsweredoneat25°Cbyusingstreptavidinsensorspreloadedwith stainedwiththioﬂavinS,andmounted.Thefullareaofthetissuesectionswas
biotinylatedNI301Aorisotypecontrolantibodies.Datawereanalyzedin scannedusinganautomatedslidescanner(OlympusVS120),at×20magniﬁcation
DataAnalysisv.8.2anddouble-referencedusingisotypeandbuffer-onlyconditions, inboth4′,6-diamidino-2-phenylindoleandtetramethylrhodaminechannels.Both
andﬁttedusinga1:1kineticmodel. numbersofandareascoveredbyATTRdepositswerequantiﬁedbyusingan
automatedimageanalysisalgorithmimplementedinacommercialimageanalysis
software(Image-ProPremier,MediaCybernetics).Datawereanalyzedbyone-way
Immunoblottings.Fordotblots,200ngofTTRtetramersandATTRﬁbrilspre- analysisofvariance(ANOVA)followedbyDunnett’smultiplecomparisontests.
paredasdescribedabovewereimmobilizedonnitrocellulosemembranesbyusing
Forallinvitroandexvivoexperimentswithhumanplasma,plasmawasused
vacuumﬁltration.Forwesternblottings,TTR-V30Mwasaggregatedfor4daysat
eitherfreshlyorinactivatedbyheatingat56°Cfor30min.
37°Cundernear-physiologicalconditionsin10mMcitricacidpH6.0,150mM
NaCl,and5mMCa2+.Sampleswereseparatedbynon-reducingSDS-PAGEwith
noheatdenaturation,topreservetheaggregates’sizes,andwereimmobilizedon Complementactivationassay.ELISAplatescoatedwithATTRwtﬁbrilsorBSA
nitrocellulosemembranesbysemi-dryblotting(ThermoFisher).Epitopemapping wereloadedwithNI301Aandincubatedwithincreasingconcentrationsoffresh
wasconductedusingacellulosemembranearrayof29overlappingpeptidesof15 humanplasmafor1hat37°C.Afterwashing,thecomplementcomplexC5b9was
amino-acidlengthand11amino-acidoverlap,whichcoveredthewholemature detectedwithaspeciﬁcantibody(Abcam)andcorrespondingsecondaryantibody
TTRproteinsequence,and15additionalpeptideswhichcoveredtheTTRleader (JacksonImmunoresearch).
peptidesequenceand13selectedTTRmutationsassociatedwithhereditaryTTR
amyloidosis.Membraneswereblocked,incubatedwithNI301Aovernightat4°C, PDAXmodel.AnimalexperimentswereconductedincompliancewiththeSwiss
anddevelopedwithHRP-conjugated,anti-human,rabbitormouseIgGantibodies federalregulationsandreceivedapprovalfromtheSwissVeterinaryService(license
(JacksonImmunoresearch)incombinationwithachemiluminescentsubstrate ZH269-14).ATTRﬁbrilswereobtainedfrompost-mortemhearttissuesofATTR-
(ThermoFisher). CMpatientsusingthedetergent-freewater-basedextractionprocedure36andwere
preparedat2mg/mLconcentrationtoconferhighviscositytotheextract.ATTR
ﬁbrilsweregraftedintoSKH1-Elitefemalemiceof2.5–3monthsofagebysub-
Immunoprecipitation.ProteinA-coatedmagneticbeads(Dynabeads,LifeTech-
cutaneousinjectionof50µLinthethighsfollowedbyi.v.administrationofthe
nologies)weresaturatedwithNI301Aoranti-TTRDakoA0002antibodiesand antibody.NI301AantibodywaslabeledwiththeﬂuorescentdyeVivoTag680
incubatedfor30minatroomtemperaturewithTTRwttetramers,orwithpatient- (PerkinElmer)fortargetbindingexperiments(NI301A-VT680)andthemouse
derivedATTRﬁbrilsfunctioningascontrols,orwithhumanplasmasamples chimericIgG2aNI301Avariant(ch.NI301A)wasusedforinvivoefﬁcacyexperi-
diluted0,10,100,1000,and10,000timesinPBSwithTween-20.Afterwashing,
ments.AnFc-inactivevariant,namedch.NI301A-LALAPG,wasgeneratedusing
theantibody–antigencomplexeswereeluteddirectlyinSDS-PAGEloadingbuffer theL234A,L235A,andP329Gsubstitutions,whichareknowntoeliminateFcγ
(80°Cfor15min)separatedbySDS-PAGEandanalyzedbywesternblottingwith receptorandcomplementfactorC1binding37.Tafamidis(Carbosynth)waspre-
theDakoA0002TTRantibody.
paredat100µg/mLinvehicle(PBS7.4,10%EtOH,10%PS80)andadministered
dailyat1mg/kgi.p.Datawereanalyzedbyone-wayortwo-wayANOVAsfollowed
Immunostaining.Frozenorparaformaldehyde(PFA)-ﬁxedtissuebiopsies byDunnett’smultiplecomparisonstestusingtheisotype-treatedgroupasreference.
obtainedfromATTR-CMpatientsandfromATTRpolyneuropathypatientswere
stainedwithCongoredbyusingPutchler’smodiﬁcations35.Immunostainingswere Humanhearttissueanalysis.TheNationalDiseaseResearchInterchangecollected
doneafterquenchingendogenousperoxidaseactivitywith3%HO inmethanol, theautopsyhearttissuesfrommaleswithheartfailure,withpreservedejection
2 2
blockingwith4%BSAand5%normalhorseandgoatserainPBS,incubationwith fraction,whodiedatanageof80yearsormore.Inallcases,thedonors(ortheirnext-
primaryantibodiesovernightat4°C,anddetectionusinggoatanti-rabbitIgG of-kin)providedinformedconsenttoprocurebiospecimensforbiomedicalresearch.
antibody(JacksonImmunoresearch)whereneeded,incombinationwiththe OnlydonorsontheCenterforDiseaseControlHighRiskcategoryanddonorswith
VectastainABCkit(VectorLaboratories)anddiaminobenzidine(Dako).NI301A cardiactumorswereexcludedfromthecollection.Sampleswereprocessedforhis-
wasusedasabiotinylatedconjugateat10nMonfrozentissuesections.Antibody tologicalanalysis.Congored-positivesampleswerestainedbyIHCwithTTRanti-
DakoA0002wasusedat1:500or1:1000dilutionsandrequiredPFApostﬁxation bodiesDakoA0002,39-44(Alexotech)andwithNI301Aasdescribedabove.
forstaining,leadingtoadifferentappearanceofthetissuesduetothedifferent
processing.Tissuescanningmicroscopywasdoneat×20magniﬁcationinbright Statisticsandreproducibility.AllgroupvaluesarepresentedasmeanandtheSD
ﬁeldandpolarizationmodeswithanOlympusVS120virtualslidemicroscope.
representedforgroupswithn>3.Statisticalanalysiswereperformedusingthe
ImmunostainingofPFA-ﬁxedparafﬁn-embeddedATTRﬁbrilgraftsinmice GraphPadPrismsoftware,usingone-wayANOVAandDunnett’smultiplecom-
wasperformedasdescribedaboveusingthefollowingprimaryantibodies:Dako parisonstestortwo-wayANOVAandBonferroni’smultiplecomparisontest.P<
A0002forTTR,Abcamab133357forCD11B,Abcamab2557(cloneNIMP-R14) 0.05wasconsideredasstatisticallysigniﬁcant.Allexperimentshavebeenrepeated
forLY6G,andWako019-19741forIBA1.
onindependentoccasionsandgeneratedsimilarresults.
Tissuecross-reactivityanalyseswereconductedbyimmunostainingusinga
biotin-conjugatedNI301Aantibodyat1,10,and30µg/mLonfrozenhumantissue
arrays(USBiomaxFDA903).Thearrayscontained90tissuesectionsrepresenting Reportingsummary.FurtherinformationonresearchdesignisavailableintheNature
30differentorganseachfromthreedifferentindividuals. ResearchReportingSummarylinkedtothisarticle.
Data availability
Fibrilextractionfromtissues.ATTRﬁbrilswereextractedfromfrozencardiac
tissuesobtainedatautopsyandsemi-puriﬁedusingthedetergent-freeprotocol Alluniquebiologicalmaterialincludedinthisarticlecanbemadeavailableupon
describedbyPrasetal.36.Thisprotocolpreservestheamyloidconformationby substantiatedrequesttothecorrespondingauthor.Sourcedataareprovidedwith
relyingonthepartialsolubilityofamyloidﬁbrilsinpurewater. thispaper.
10 NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
Received: 24August 2020; Accepted: 20April2021; 26. Benson,M.D.etal.Inotersentreatmentforpatientswithhereditary
transthyretinamyloidosis.N.Engl.J.Med.379,22–31(2018).
27. Maurer,M.S.etal.Tafamidistreatmentforpatientswithtransthyretin
amyloidcardiomyopathy.N.Engl.J.Med.379,1007–1016(2018).
28. Berk,J.L.etal.Repurposingdiﬂunisalforfamilialamyloidpolyneuropathy:a
randomizedclinicaltrial.JAMA310,2658–2667(2013).
References 29. Sevigny,J.etal.TheantibodyaducanumabreducesAβplaquesinAlzheimer’s
disease.Nature537,50–56(2016).
1. Gertz,M.A.etal.Diagnosis,prognosis,andtherapyoftransthyretin
amyloidosis.J.Am.Coll.Cardiol.66,2451–2466(2015). 30. Klein,G.etal.Gantenerumabreducesamyloid-βplaquesinpatientswith
2. Alshehri,B.,D’Souza,D.G.,Lee,J.Y.,Petratos,S.&Richardson,S.J.Thediversity prodromaltomoderateAlzheimer’sdisease:aPETsubstudyinterimanalysis.
ofmechanismsinﬂuencedbytransthyretininneurobiology:development,disease AlzheimersRes.Ther.11,101(2019).
andendocrinedisruption.J.Neuroendocrinol.27,303–323(2015). 31. Greenberg,S.M.etal.CerebralamyloidangiopathyandAlzheimerdisease—
3. Schmidt,M.etal.Cryo-EMstructureofatransthyretin-derivedamyloidﬁbril onepeptide,twopathways.Nat.Rev.Neurol.16,30–42(2020).
fromapatientwithhereditaryATTRamyloidosis.Nat.Commun.10,5008 32. Weihofen,A.etal.Developmentofanaggregate-selective,human-derivedα-
synucleinantibodyBIIB054thatamelioratesdiseasephenotypesin
(2019).
Parkinson’sdiseasemodels.Neurobiol.Dis.124,276–288(2019).
4. Ando,Y.etal.Guidelineoftransthyretin-relatedhereditaryamyloidosisfor
clinicians.Orphanet.J.RareDis.8,31(2013). 33. Nobuhara,C.K.etal.Tauantibodytargetingpathologicalspeciesblocks
neuronaluptakeandinterneuronpropagationoftauinvitro.Am.J.Pathol.
5. Maurer,M.S.etal.Genotypeandphenotypeoftransthyretincardiac
187,1399–1412(2017).
amyloidosis:THAOS(TransthyretinAmyloidOutcomeSurvey).J.Am.Coll.
Cardiol.68,161–172(2016). 34. Maier,M.etal.Ahuman-derivedantibodytargetsmisfoldedSOD1and
6. Tanskanen,M.etal.Senilesystemicamyloidosisaffects25%ofthe amelioratesmotorsymptomsinmousemodelsofamyotrophiclateral
veryagedandassociateswithgeneticvariationinalpha2-macroglobulin sclerosis.Sci.Transl.Med.10,eaah3924(2018).
andtau:apopulation-basedautopsystudy.Ann.Med.40,232–239 35. Elghetany,M.T.,Saleem,A.&Barr,K.TheCongoredstainrevisited.Ann.
Clin.Lab.Sci.19,190–195(1989).
(2008).
36. Pras,M.,Schubert,M.,Zucker-Franklin,D.,Rimon,A.&Franklin,E.C.The
7. Mohammed,S.F.etal.Leftventricularamyloiddepositioninpatientswith
heartfailureandpreservedejectionfraction.JACCHeartFail.2,113–122 characterizationofsolubleamyloidpreparedinwater.J.Clin.Invest.47,
924–933(1968).
(2014).
37. Lo,M.etal.Effector-attenuatingsubstitutionsthatmaintainantibodystability
8. González-López,E.etal.Wild-typetransthyretinamyloidosisasacauseof
heartfailurewithpreservedejectionfraction.Eur.HeartJ.36,2585–2594 andreducetoxicityinmice.J.Biol.Chem.292,3900–3908(2017).
(2015). 38. Richards,D.B.etal.Therapeuticclearanceofamyloidbyantibodiestoserum
amyloidPcomponent.NEJM.373,1106–1114(2015).
9. BennaniSmires,Y.etal.Pilotstudyforleftventricularimagingphenotypeof
39. Richards,D.B.etal.RepeatdosesofantibodytoserumamyloidPcomponent
patientsover65yearsoldwithheartfailureandpreservedejectionfraction:
clearamyloiddepositsinpatientswithsystemicamyloidosis.Sci.Transl.
thehighprevalenceofamyloidcardiomyopathy.Int.J.Cardiovasc.Imaging
32,1403–1413(2016). Med.10,eaan3128(2018).
10. Cavalcante,J.L.etal.Cardiacamyloidosisisprevalentinolderpatientswith
aorticstenosisandcarriesworseprognosis.J.Cardiovasc.Magn.Reson.19,98 Acknowledgements
(2017).
Wethankthepatientsandtheirrelativeswhodonatedthebiospecimensusedinthis
11. Scully,P.R.etal.Prevalenceofcardiacamyloidosisinpatientsreferredfor
transcatheteraorticvalvereplacement.J.Am.Coll.Cardiol.71,463–464 study,andacknowledgepartialfundingthroughaEurostarsgrant(E!9036).Wealso
thanktheNationalDiseaseResearchInterchangeforprovidingbiospecimens;Dr.Fab-
(2018).
riceHeitz,Neurimmune,andGeryBarmettler,CenterforMicroscopyandImage
12. Gertz,M.A.,Mauermann,M.L.,Grogan,M.&Coelho,T.Advancesinthe
AnalysisUniversityofZurich,forelectronmicroscopyimaging;Dr.StefanSchauer,
treatmentofhereditarytransthyretinamyloidosis:areview.BrainBehav.9,
FunctionalGenomicsCenterETHandUniversityofZurich,forhissupportwithkinetic
e01371(2019).
bindingexperimentsusingSPR;andtheAntibodyTechnologyGroupatNeurimmune
13. Goldsteins,G.etal.Exposureofcrypticepitopesontransthyretinonlyin
forantibodycloningandexpression.
amyloidandinamyloidogenicmutants.Proc.NatlAcad.Sci.USA96,
3108–3113(1999).
14. Palaninathan,S.K.Nearly200X-raycrystalstructuresoftransthyretin:what Author contributions
dotheytellusaboutthisproteinandthedesignofdrugsforTTR A.M.andJ.G.conceivedandledthestudy.A.M.,A.H.,C.Huy,E.V.andB.C.designed
amyloidoses?Curr.Med.Chem.19,2324–2342(2012). and/orperformed,and/oranalyzedexperiments.C.Hock,T.D.,O.B.S.andM.J.S.pro-
15. Lai,Z.,Colón,W.&Kelly,J.W.Theacid-mediateddenaturationpathwayof videdmaterialsandscientiﬁcguidance.B.C.,C.Hock,R.M.N.andJ.G.contributedto
transthyretinyieldsaconformationalintermediatethatcanself-assembleinto experimentaldesignandinterpretationofdata,andcriticallyrevisedthemanuscript.
amyloid.Biochemistry35,6470–6482(1996). A.M.wrotethemanuscript.
16. Arndt,J.W.etal.Structuralandkineticbasisfortheselectivityof
aducanumabforaggregatedformsofamyloid-β.Sci.Rep.8,6412(2018).
Competing interests
17. Bodin,K.etal.AntibodiestohumanserumamyloidPcomponenteliminate
visceralamyloiddeposits.Nature468,93–97(2010). A.M.,A.H.,C.Huy,E.V.,B.C.,C.Hock,R.M.N.andJ.G.areorwere(E.V.)employeesof
18. Martinez-Naharro,A.etal.MagneticResonanceinTransthyretinCardiac Neurimmune.O.B.S.participatesinclinicaltrialsforAlnylamandProthenaPharma-
Amyloidosis.J.Am.Coll.Cardiol.70,466–477(2017). ceuticals,andhasservedinAdvisoryboardsforPﬁzer,Alnylam,Akcea,Prothena,and
19. Treibel,T.A.etal.Extracellularvolumequantiﬁcationbydynamic IntelliaPharmaceuticals,andhasparticipatedineducationalactivitiessponsoredby
equilibriumcardiaccomputedtomographyincardiacamyloidosis.J. AlnylamandAkceaPharmaceuticals.T.D.participatesinclinicaltrialsandhasservedin
Cardiovasc.Comput.Tomogr.9,585–592(2015). AdvisoryboardsforAlnylam,Akcea,Pﬁzer,andProthenaPharmaceuticals.M.J.S.does
20. Damy,T.etal.Clinical,ECGandechocardiographiccluestothediagnosisof nothavecompetinginterest.
TTR-relatedcardiomyopathy.OpenHeart3,e000289(2016).
21. Arvidsson,S.,Pilebro,B.,Westermark,P.,Lindqvist,P.&Suhr,O.B.Amyloid Additional information
cardiomyopathyinhereditarytransthyretinV30Mamyloidosis-impactofsex SupplementaryinformationTheonlineversioncontainssupplementarymaterial
andamyloidﬁbrilcomposition.PLoSONE10,e0143456(2015). availableathttps://doi.org/10.1038/s41467-021-23274-x.
22. Kristen,A.V.etal.Cardiacamyloidload:aprognosticandpredictive
biomarkerinpatientswithlight-chainamyloidosis.J.Am.Coll.Cardiol.68, CorrespondenceandrequestsformaterialsshouldbeaddressedtoA.M.
13–24(2016).
23. Xu,Z.,Paparcone,R.&Buehler,M.J.Alzheimer’sabeta(1-40)amyloidﬁbrils PeerreviewinformationNatureCommunicationsthanksMorieA.Gertzandtheother,
featuresize-dependentmechanicalproperties.Biophys.J.98,2053–2062 anonymous,reviewer(s)fortheircontributiontothepeerreviewofthiswork.Peer
(2010). reviewerreportsareavailable.
24. demSiepen,F.A.etal.Predictorsofsurvivalstratiﬁcationinpatientswith
wild-typecardiacamyloidosis.Clin.Res.Cardiol.https://doi.org/10.1007/ Reprintsandpermissioninformationisavailableathttp://www.nature.com/reprints
s00392-017-1167-1(2017).
25. Adams,D.etal.Patisiran,anRNAitherapeutic,forhereditarytransthyretin Publisher’snoteSpringerNatureremainsneutralwithregardtojurisdictionalclaimsin
amyloidosis.N.Engl.J.Med.379,11–21(2018). publishedmapsandinstitutionalafﬁliations.
NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications 11

NEW PAGE

ARTICLE
NATURECOMMUNICATIONS|https://doi.org/10.1038/s41467-021-23274-x
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation,distributionandreproductioninanymediumorformat,aslongasyougive
appropriatecredittotheoriginalauthor(s)andthesource,providealinktotheCreative
Commonslicense,andindicateifchangesweremade.Theimagesorotherthirdparty
materialinthisarticleareincludedinthearticle’sCreativeCommonslicense,unless
indicatedotherwiseinacreditlinetothematerial.Ifmaterialisnotincludedinthe
article’sCreativeCommonslicenseandyourintendeduseisnotpermittedbystatutory
regulationorexceedsthepermitteduse,youwillneedtoobtainpermissiondirectlyfrom
thecopyrightholder.Toviewacopyofthislicense,visithttp://creativecommons.org/
licenses/by/4.0/.
©TheAuthor(s)2021
12 NATURECOMMUNICATIONS|        (2021) 12:3142 |https://doi.org/10.1038/s41467-021-23274-x|www.nature.com/naturecommunications

NEW PAGE